


Pharmaceuticals & Biotechnology | Small Cap
Lyka Labs Ltd, operating within the Healthcare Services sector, showcases a mixed financial performance. The company demonstrates strong solvency and profitability, driven by high equity, return on capital employed, and return on assets. However, liquidity remains a significant concern due to negligible current, quick, and cash ratios. Efficiency is also a challenge, with low turnover ratios indicating poor asset utilization. The company shows promise in operating profit and asset growth, but struggles with revenue and net income growth. While interest coverage is reasonable, the absence of equity dividend coverage raises concerns. Overall, Lyka Labs exhibits financial stability and profitability, but needs to address its liquidity and efficiency challenges to ensure long-term sustainability. The weighted average calculation method considers recent years more heavily, so improvements in recent performance could positively impact future assessments.
Lyka Labs Ltd, operating within the Healthcare Services sector, showcases a mixed financial performance. The company demonstrates strong solvency and profitability, driven by high equity, return on capital employed, and return on assets. However, liquidity remains a significant concern due to negligible current, quick, and cash ratios. Efficiency is also a challenge, with low turnover ratios indicating poor asset utilization. The company shows promise in operating profit and asset growth, but struggles with revenue and net income growth. While interest coverage is reasonable, the absence of equity dividend coverage raises concerns. Overall, Lyka Labs exhibits financial stability and profitability, but needs to address its liquidity and efficiency challenges to ensure long-term sustainability. The weighted average calculation method considers recent years more heavily, so improvements in recent performance could positively impact future assessments.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-8.27
Industry Median
31.12
Small Cap Median
27.82
P/E RATIO
-26.63
P/B RATIO
2.89
Industry Median
3.28
Small Cap Median
2.78
P/S RATIO
2.09
Industry Median
3.42
Small Cap Median
2.71
Others
PEG RATIO
0.00
EV/EBITDA RATIO
-290.16
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹74.83 as on Jul 1, 2026.
The company's growth performance is mixed. While operating profit and asset growth show promise, revenue and net income growth are lacking. Earnings per share growth is also a concern. This suggests potential for future expansion if revenue and profitability can be improved. The weighted average calculation, which gives more weight to recent data, suggests that improvements in operating profit and asset growth could drive future assessments.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 125.58 | -52.06 | 19.35 | 24.32 | -7.25 |
| Operating Profit Growth Rate | 405 | -83.17 | -5.88 | 12.5 | -122.22 |
| Earnings Per Share (EPS) Growth | -437.22 | -131.64 | -82.56 | -398.67 | -225.45 |
| Asset Growth Rate | -2.11 | -18.28 | 3.29 | 12.1 | -0.57 |
| Net Income Growth Rate | -480 | -134.21 | -76.92 | -366.67 | -225 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 2 | SMS Lifesciences India Ltd | 6.59 | 21.63 | Undervalued | 45.00 | 58.80 | 19.00 |
| 3 | Infinium Pharmachem Ltd | 6.42 | 26.92 | Neutral | 22.00 | 6.43 | 14.00 |
| 4 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 58.43 | Neutral | 7.00 | 1.40 | 4.00 |
| 5 | Albert David Ltd | 5.63 | -279.90 | Neutral | 5.00 | -2.62 | -1.00 |
| 6 | BPL Ltd | 5.46 | -30.53 | Neutral | -4.82 | -1.69 | -8.55 |
| 7 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 8 | Quest Laboratories Ltd | 5.27 | 9.84 | Neutral | 18.00 | 9.16 | 15.00 |
| 9 | Sotac Pharmaceuticals Ltd | 5.27 | 18.18 | Neutral | 18.00 | 4.45 | 6.00 |
| 10 | Lyka Labs Ltd | 4.77 | -26.63 | Neutral | -4.00 | -8.93 | -10.00 |
| 11 | Krebs Biochemicals & Industries Ltd | 4.16 | -4.34 | Highly Undervalued | -4.00 | -7.85 | -4.00 |
| 12 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral